Robert Gallotto is the founder of Anagram Therapeutics. Anagram Therapeutics has raised $250M in total funding. Latest round: Growth.
Robert Gallotto is a co-founder, President, and Chief Executive Officer of Anagram Therapeutics, a company focused on rare diseases. He is an experienced pharmaceutical executive with a 35-year track record. Prior to Anagram, he co-founded Alcresta Therapeutics, where he launched the RELiZORB product, and also co-founded Allena Pharmaceuticals. He holds a B.S. in biology from Stonehill College.
Full founder directory · Investor directory · Company funding database · Fundraising library